These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 32348108)
21. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect? Li Y; Rosenblit PD Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238 [TBL] [Abstract][Full Text] [Related]
23. A potent α/β-peptide analogue of GLP-1 with prolonged action in vivo. Johnson LM; Barrick S; Hager MV; McFedries A; Homan EA; Rabaglia ME; Keller MP; Attie AD; Saghatelian A; Bisello A; Gellman SH J Am Chem Soc; 2014 Sep; 136(37):12848-51. PubMed ID: 25191938 [TBL] [Abstract][Full Text] [Related]
24. Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals. Wu Y; Ji T; Lv J; Wang Z Life Sci; 2020 Sep; 257():118025. PubMed ID: 32598933 [TBL] [Abstract][Full Text] [Related]
25. Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes? Doggrell SA Expert Opin Pharmacother; 2018 Oct; 19(15):1655-1661. PubMed ID: 30234389 [TBL] [Abstract][Full Text] [Related]
26. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors. Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365 [TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes. Kirk RK; Pyke C; von Herrath MG; Hasselby JP; Pedersen L; Mortensen PG; Knudsen LB; Coppieters K Diabetes Obes Metab; 2017 May; 19(5):705-712. PubMed ID: 28094469 [TBL] [Abstract][Full Text] [Related]
28. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Lund A; Knop FK; Vilsbøll T Eur J Intern Med; 2014 Jun; 25(5):407-14. PubMed ID: 24694879 [TBL] [Abstract][Full Text] [Related]
29. Effects of Glucagon-like peptide 1 (GLP-1) analogs in the hippocampus. Diz-Chaves Y; Herrera-Pérez S; González-Matías LC; Mallo F Vitam Horm; 2022; 118():457-478. PubMed ID: 35180937 [TBL] [Abstract][Full Text] [Related]
30. Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis. Cameron-Vendrig A; Reheman A; Siraj MA; Xu XR; Wang Y; Lei X; Afroze T; Shikatani E; El-Mounayri O; Noyan H; Weissleder R; Ni H; Husain M Diabetes; 2016 Jun; 65(6):1714-23. PubMed ID: 26936963 [TBL] [Abstract][Full Text] [Related]
31. Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. Alavi SE; Cabot PJ; Moyle PM Mol Pharm; 2019 Jun; 16(6):2278-2295. PubMed ID: 31050435 [TBL] [Abstract][Full Text] [Related]
32. [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist]. Zheng YC Yao Xue Xue Bao; 2015 Dec; 50(12):1668-72. PubMed ID: 27169293 [TBL] [Abstract][Full Text] [Related]
33. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'. Skow MA; Bergmann NC; Knop FK Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961 [TBL] [Abstract][Full Text] [Related]
34. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Baggio LL; Ussher JR; McLean BA; Cao X; Kabir MG; Mulvihill EE; Mighiu AS; Zhang H; Ludwig A; Seeley RJ; Heximer SP; Drucker DJ Mol Metab; 2017 Nov; 6(11):1339-1349. PubMed ID: 29107282 [TBL] [Abstract][Full Text] [Related]
35. A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency. Wang X; Yun Y; Chen L; Guo S; Niu B; Fang J; Yuan Q; Shen J; Xie X; Wang K Bioorg Med Chem; 2024 Jun; 107():117761. PubMed ID: 38795571 [TBL] [Abstract][Full Text] [Related]
36. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Morales J Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467 [TBL] [Abstract][Full Text] [Related]
37. A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat. Han L; Hölscher C; Xue GF; Li G; Li D Neuroreport; 2016 Jan; 27(1):23-32. PubMed ID: 26555034 [TBL] [Abstract][Full Text] [Related]
38. Xenopus-derived glucagon-like peptide-1 and polyethylene-glycosylated glucagon-like peptide-1 receptor agonists: long-acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities. Han J; Fei Y; Zhou F; Chen X; Zhang Y; Liu L; Fu J Br J Pharmacol; 2018 Feb; 175(3):544-557. PubMed ID: 29171021 [TBL] [Abstract][Full Text] [Related]
39. The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling. Dods RL; Donnelly D Biosci Rep; 2015 Nov; 36(1):e00285. PubMed ID: 26598711 [TBL] [Abstract][Full Text] [Related]
40. New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide. Nakane A; Gotoh Y; Ichihara J; Nagata H Anal Biochem; 2015 Dec; 491():23-30. PubMed ID: 26341912 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]